跳至主要内容
临床试验/NCT06720610
NCT06720610尚未招募4 期

Comparison of the Effectiveness of Vonoprazan and Esomeprazole in Improving Initial Symptoms in Patients with Erosive Esophagitis: a Double-Blind Randomized Trial

Indonesia University5 个研究点 分布在 1 个国家目标入组 216 人开始时间: 2024年12月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
尚未招募
入组人数
216
试验地点
5
主要终点
Number of Participants with Symptoms Resolution of Erosive Esophagitis

研究概览

简要总结

The goal of this clinical trial is to compare drug vonoprazan vs esomeprazole effectiveness to relieve early symptoms in Erosive Esophagitis Patients. It will also learn about the safety of both modalities. The main questions it aims to answer are:

How does the effectiveness of Vonoprazan compare with Esomeprazole in improving early symptoms of erosive esophagitis patients in the Indonesian population?

Researchers will compare drug vonoprazan to a esomeprazole with a look-alike packaging to see their effect to reduce early symptoms of erosive esophagitis.

Participants will:

  • Take drug vonoprazan 20mg or esomeprazole 40mg one time every day for 2 weeks
  • Visit the clinic once every weeks for followup (Gastro Esophageal Reflux Disease-Quetionnaire measurement)
  • Keep a diary of their adverse effect occurence and every variable data based on Gastro Esophageal Reflux Disease-Questionnaire.

详细描述

Based on the calculation using the formula for comparing two population proportions, the minimum estimated sample size is 97 samples for each group. Considering a potential 10% drop-out rate, the estimated sample size increases to 108 samples per group. Therefore, the total minimum sample required for this study is 216 samples for both groups.

All the patients will screened using the Gastro Esophageal Reflux Disease-Quetionnaire (6 questions, 4 answer options, covering the last 7 days) and collected through RedCap. After that all eligible patients will undergo endoscopic examination that performed by gastroenterology specialists or trained internists.

Included patients who consume any Proton Pump Inhibiotr or Potassium-competitive acid blockers within 2 weeks prior to this study will undergo wash-out period for 2 weeks. Patients are monitored weekly during the wash-out period. Medication reminders are sent via instant messaging at least twice per week. Adverse Event will be monitored by research assistants in coordination with the patient's primary physician.

All the data will analyzed blindly with Chi-square or Fisher's exact test for categorical data and logistic regression for confounding factors. At the end of the study, the pharmacy team will reveal the group allocation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged >18 years with a GERD-Q score of
  • Diagnosed with erosive esophagitis by endoscopy. (Los Angeles Classification A-D)
  • Patients are willing to undergo a series of therapeutic management.

排除标准

  • Patients with a history of allergy to PCAB or PPI groups.
  • Patients with gastric and/or duodenal ulcers.
  • Patients with Helicobacter pylori infection.
  • Patients with a history of significant systemic disease disorders affecting the esophagus and stomach.
  • Patients with a history of malignant disease related to the esophagus and/or stomach.
  • Patients with a history of esophageal and/or gastric surgery.
  • Pregnant patients

研究组 & 干预措施

Vonoprazan

Experimental

Each randomized patients will consume 20mg of vonoprazan once a day for 14 days consecutively

干预措施: Vonoprazan 20 mg (Drug)

Esomeprazole

Active Comparator

Each randomized patients will consume 40mg of esomeprazole once a day for 14 days consecutively

干预措施: Esomeprazole (Drug)

结局指标

主要结局

Number of Participants with Symptoms Resolution of Erosive Esophagitis

时间窗: 14 days (two weeks)

Participants achieved a, * complete resolution if they scored a GERD-Q questionnaire of 0 from scale 0-18. - sufficient relief if they scored GERD-Q of 1 or 0 (No. 1,2,5,6) * persistent response if they score GERD-Q of 2 or more in any single question.

次要结局

  • Number of Participants with Adverse Event(14 days (two weeks))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ari Fahrial Syam

Dean of Faculty of Medicine Universitas Indonesia

Indonesia University

研究点 (5)

Loading locations...

相似试验